Vical To Present TransVax CMV Vaccine Phase 2 Results at ICAAC and Host Concurrent Conference Call and Webcast
SAN DIEGO, Sept. 9, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced plans to present final results from the company's Phase 2 trial evaluating the potential for its TransVax™ therapeutic DNA vaccine to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed hematopoietic cell transplant (HCT) recipients. The company's abstract was accepted for a late-breaker session at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC, Boston – September 12-15).
The company will release summary results from the trial before the opening of trading on Tuesday, September 14, and conduct an audio-only conference call and audio/slide webcast at 11:15 a.m. Eastern Time on Tuesday, September 14, concurrent with the session at ICAAC, to discuss additional details of the results with invited analysts and institutional investors. CMV and organ transplant expert Mark D. Pescovitz, M.D., Professor of Surgery and Microbiology & Immunology, and Vice Chair of Research in Surgery at the Indiana University School of Medicine, will join Vical management on the call. The call is open on a listen-only basis to any interested parties. The webcast audio and slides also will be available live and archived through the Events page of the company's website at <http://www.globenewswire.com/newsroom/ctr?d=201111&l=2&a=www.vical.com&u=http%3A%2F%2Fwww.vical.com%2F> www.vical.com<http://www.vical.com>.
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (888) 205-6648, or (913) 981-5543 for international participants, and reference confirmation code 4384312. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter replay passcode 4384312. The call also will be available live and archived through the Events page at <http://www.globenewswire.com/newsroom/ctr?d=201111&l=3&a=www.vical.com&u=http%3A%2F%2Fwww.vical.com> www.vical.com<http://www.vical.com>. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at firstname.lastname@example.org<http://www.globenewswire.com/newsroom/ctr?d=201111&l=3&a=info%40vical.com&u=mailto%3Ainfo%40vical.com>.
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at <http://www.globenewswire.com/newsroom/ctr?d=201111&l=5&a=www.vical.com&u=http%3A%2F%2Fwww.vical.com%2F> www.vical.com<http://www.vical.com>.
The Vical Incorporated logo is available at <http://www.globenewswire.com/newsroom/ctr?d=201111&l=6&u=http%3A%2F%2Fwww.globenewswire.com%2Fnewsroom%2Fprs%2F%3Fpkgid%3D5768> http://www.globenewswire.com/newsroom/prs/?pkgid=5768
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether Vical or others will continue development of TransVax™ or any other product candidates; whether TransVax™ or any other product candidates will be shown to be safe and effective; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market TransVax™ or any other product candidates; the dependence of the company on its collaborative partners; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
CONTACT: Vical Incorporated Alan R. Engbring (858) 646-1127 www.vical.com
Posted: September 2010